Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab

por Florou, Despoina, Katsara, Maria, Feehan, Jack, Dardiotis, Efthimios, Apostolopoulos, Vasso
Publicado 2020

Tetracyclines Diminish In Vitro IFN-γ and IL-17-Producing Adaptive and Innate Immune Cells in Multiple Sclerosis

por Florou, Despoina T., Mavropoulos, Athanasios, Dardiotis, Efthymios, Tsimourtou, Vana, Siokas, Vasileios, Aloizou, Athina-Maria, Liaskos, Christos, Tsigalou, Christina, Katsiari, Christina, Sakkas, Lazaros I., Hadjigeorgiou, Georgios, Bogdanos, Dimitrios P.
Publicado 2021